Holen Sie sich die Stockscreener-App
24.31
1.94%
-0.48
Handel nachbörslich:
24.37
0.06
+0.25%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.79
Offen:
$24.675
24-Stunden-Volumen:
31.03M
Relative Volume:
0.75
Marktkapitalisierung:
$138.21B
Einnahmen:
$62.46B
Nettoeinkommen (Verlust:
$7.88B
KGV:
17.62
EPS:
1.38
Netto-Cashflow:
$11.22B
1W Leistung:
+0.21%
1M Leistung:
+0.50%
6M Leistung:
-9.12%
1J Leistung:
-20.99%
1-Tages-Spanne:
$24.23
$24.73
1-Wochen-Bereich:
$24.23
$25.54
52-Wochen-Spanne:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.31 | 140.94B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
808.11 | 729.58B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
166.22 | 405.32B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
188.52 | 336.11B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
116.18 | 227.85B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
69.00 | 318.59B | 43.59B | 15.04B | 10.74B | 3.3766 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Josh Brown on Pfizer (PFE): ‘I Was Dead Wrong, There’s No Turnaround’ - Insider Monkey
Migraine Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored | GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co - Barchart.com
Morgan Stanley Maintains a Hold on Pfizer (PFE) - Insider Monkey
Pfizer Inc. (PFE) Finalizes Global Licensing Agreement with 3sbio, Inc. - Insider Monkey
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY - Yahoo Finance
Unpacking the mRNA Revolution: BioNTech and Pfizer's Strategic Edge in a Post-Pandemic Era - AInvest
Pfizer and Chinese biotech company finalize global licensing deal for cancer drug - Latest news from Azerbaijan
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer’s New Vaccine Study: A Potential Game Changer in China - TipRanks
Pfizer’s PAXLOVID Study: Real-World Insights on COVID-19 Treatment - The Globe and Mail
Pfizer’s Comeback Is Underway (NYSE:PFE) - Seeking Alpha
Pfizer/BioNTech, Moderna win EU backing for updated COVID shots - Seeking Alpha
BioNTech and Pfizer’s New COVID-19 Vaccine Awaits EU Approval - TipRanks
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer and 3SBio conclude licensing deal for SSGJ-707 - Yahoo Finance
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union - BioSpace
Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug - South China Morning Post
PFE Stock Quote Price and Forecast - CNN
Pfizer Completes Licensing Agreement with 3SBio - BioSpace
Pfizer and BioNTech Announce Marketing Authorization Recommendation for LP.8.1-Adapted COVID-19 Vaccine Enhancing Immune Response Against Emerging Variants - Quiver Quantitative
Pfizer's Latest COVID Vaccine Shows Enhanced Protection Against XFG and NB.1.8.1 Variants - Stock Titan
Pfizer’s ‘Depo-Provera’ Increases Risk of Brain Tumours 3.5 - GlobeNewswire
Pfizer (PFE) Faces Legal Challenges Over Depo-Provera's Increased Brain Tumor Risk - simplywall.st
Pfizer’s New Phase 1 Study: A Potential Game-Changer? - TipRanks
Pfizer’s New Study on COVID-19 Treatment: What Investors Need to Know - TipRanks
Pfizer’s Pediatric Pantoprazole Study: A Market Watch - TipRanks
Pfizer Is Butting Up Against Its 200-Day Line. Will It Soon Be A Buy? - Investor's Business Daily
Pfizer Bolsters Oncology Pipeline with $1.25B 3SBio Deal - Contract Pharma
Pfizer faces lawsuits over Depo-Provera cancer risk (PFE:NYSE) - Seeking Alpha
Pfizer’s ‘Depo-Provera’ Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control Pill According to New Study as Litigation Overseen by Levin Papantonio Rises to Over 550 Lawsuits - GlobeNewswire
Pfizer licenses cancer immunotherapy from 3SBio in $1.25 billion deal - Investing.com
Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings - The Globe and Mail
Ex-Dividend Reminder: GE HealthCare Technologies, Pfizer and Old Second Bancorp - Nasdaq
Pfizer Nears Major Bottom: A Turning Point for Investors? - FXEmpire
Pfizer: Building The Next Oncology Empire - Seeking Alpha
Why Regency Centers, Tyson Foods, And Pfizer Are Winners For Passive Income - Yahoo Finance
Here's What To Expect From Pfizer's Non-Oncology Drugs In Q2 Earnings - Barchart.com
Pfizer Stock (PFE) Opinions on Stagnant Performance and Policy Risks - Quiver Quantitative
Is Pfizer Inc. a good long term investmentRecord-setting profit potential - Autocar Professional
What analysts say about Pfizer Inc. stockBreakthrough profits - jammulinksnews.com
Pfizer Inc. (NYSE:PFE) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed? - Yahoo Finance
Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II - insights.citeline.com
Request for Proposals: Pfizer Independent Medical Education Grant Program - fundsforNGOs
Lobbying Update: $3,490,000 of PFIZER INC. lobbying was just disclosed - Nasdaq
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? - AOL.com
What drives Pfizer Inc. stock priceFree Stock Market Return Analysis - Jammu Links News
Pfizer Inc. Stock Analysis and ForecastOutstanding stock performance - jammulinksnews.com
Can Pfizer Limited (PFIZER) Maintain Its ValuationFree Market Volatility Navigation Tips - Jammu Links News
Pfizer’s Discounted Stock Offers Yield, But Risks Linger - Finimize
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):